Cargando…

Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex

BACKGROUND: Tuberous sclerosis complex (TSC) is a genetic disorder that cause tumors to form in many organs. These lesions may lead to epilepsy, autism, developmental delay, renal, and pulmonary failure. Loss of function mutations in TSC1 and TSC2 genes by aberrant activation of the mechanistic targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Yiyang, Zhang, Erik Y., Liu, Jie, Yu, Jane J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433150/ https://www.ncbi.nlm.nih.gov/pubmed/32807195 http://dx.doi.org/10.1186/s13023-020-01490-w

Ejemplares similares

Radiological Characteristics of Renal Lesions During Tuberous Sclerosis Complex: Impact of Mechanistic Target of Rapamycin Inhibitor Treatment
por: Pfirmann, Pierre, et al.
Publicado: (2022)

Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality?
por: Kang, Michael Yoon, et al.
Publicado: (2017)

Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017)

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2011)

Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
por: Govindarajan, Baskaran, et al.
Publicado: (2012)

Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2013)

Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis
por: Lin, Yu-Ting, et al.
Publicado: (2022)

Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex
por: Sato, Atsushi, et al.
Publicado: (2012)

Antiepileptic Effect and Safety Profile of Rapamycin in Pediatric Patients With Tuberous Sclerosis Complex
por: Sadowski, Krzysztof, et al.
Publicado: (2022)

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex
por: Ji, Shuang, et al.
Publicado: (2017)

Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
por: Rauktys, Aubrey, et al.
Publicado: (2008)

Rapamycin-Insensitive Up-Regulation of Adipocyte Phospholipase A2 in Tuberous Sclerosis and Lymphangioleiomyomatosis
por: Li, Chenggang, et al.
Publicado: (2014)

Rapamycin therapy for neonatal tuberous sclerosis complex with cardiac rhabdomyomas: A case report and review
por: Mao, Shanshan, et al.
Publicado: (2017)

Safety of inactivated COVID-19 vaccine in tuberous sclerosis complex patients with epilepsy treated with rapamycin
por: Lu, Qian, et al.
Publicado: (2022)

Mechanism of Activation of Mechanistic Target of Rapamycin Complex 1 by Methionine
por: Kitada, Munehiro, et al.
Publicado: (2020)

Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
por: Querfurth, Henry, et al.
Publicado: (2021)

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)
por: Trindade, Anil J., et al.
Publicado: (2013)

Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
por: Cabrera-López, Cristina, et al.
Publicado: (2012)

The Efficacy and Safety of Rapamycin in Children with Tuberous Sclerosis: A Cross-sectional Study
por: TEHRANI, Fateme, et al.
Publicado: (2023)

Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis
por: YANG, GUANG, et al.
Publicado: (2015)

Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
por: Li, Min, et al.
Publicado: (2019)

Tubers and Tumors Are CLIPped Together in Tuberous Sclerosis Complex
por: Dang, Louis
Publicado: (2022)

Mechanistic Target of Rapamycin Pathway in Epileptic Disorders
por: Kim, Jang Keun, et al.
Publicado: (2019)

Tuberous Sclerosis Associated with Polycystic Kidney Disease: Effects of Rapamycin after Renal Transplantation
por: Rosado, C., et al.
Publicado: (2013)

Tuberous Sclerosis Complex in Autism
por: Guo, Xin, et al.
Publicado: (2012)

Tuberous sclerosis complex for the pulmonologist
por: Rebaine, Yasmine, et al.
Publicado: (2021)

Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
por: Lee, Nancy, et al.
Publicado: (2009)

The Role of Mechanistic Target of Rapamycin (mTOR) Complexes Signaling in the Immune Responses
por: Soliman, Ghada A.
Publicado: (2013)

Enhanced activation of mechanistic target of rapamycin complex 1 signaling in eruptive xanthomas
por: Huang, Yan, et al.
Publicado: (2023)

The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition
por: Lee, Yu Seol, et al.
Publicado: (2018)

Deep learning in rare disease. Detection of tubers in tuberous sclerosis complex
por: Sánchez Fernández, Iván, et al.
Publicado: (2020)

The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway
por: Hartman, Tiffiney R., et al.
Publicado: (2009)

Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex: A Double-Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of Topically Applied Rapamycin
por: Koenig, Mary Kay, et al.
Publicado: (2012)

Mechanistic target of rapamycin complex 1 signaling regulates cell proliferation, cell survival, and differentiation in regenerating zebrafish fins
por: Hirose, Kentaro, et al.
Publicado: (2014)

Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
por: Krueger, Darcy A., et al.
Publicado: (2013)

A Chinese Tuberous Sclerosis Complex Family and a Novel Tuberous Sclerosis Complex-2 Mutation
por: Luo, Rong, et al.
Publicado: (2015)

Translatome analysis of Tuberous Sclerosis Complex-1 patient-derived neural progenitor cells reveal rapamycin-dependent and independent alterations
por: Aksoylu, Inci S., et al.
Publicado: (2023)

Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
por: Aksoylu, Inci S., et al.
Publicado: (2023)

Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
por: Murray, James T., et al.
Publicado: (2018)

Mechanistic Target of Rapamycin Complex 2 Regulation of the Primary Human Trophoblast Cell Transcriptome
por: Rosario, Fredrick J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4ql9ggost6oefnk12ji27h2ipt